Valuation: Freenome, Inc.

Market Cap 137.21Cr 122.53Cr 113.19Cr 102.58Cr 191.91Cr 13TCr 195.08Cr 1.36TCr 539.27Cr 6.82TCr 514.93Cr 503.98Cr 22TCr P/E 2026 *
-6.48x
P/E 2027 * -5.72x
Enterprise Value 137.21Cr 122.53Cr 113.19Cr 102.58Cr 191.91Cr 13TCr 195.08Cr 1.36TCr 539.27Cr 6.82TCr 514.93Cr 503.98Cr 22TCr EV / Sales 2026 *
13.4x
EV / Sales 2027 * 12.1x
Free-Float
74.05%
Yield 2026 *
-
Yield 2027 * -
1 day+11.85%
1 week+19.66%
Current month-10.73%
1 month-10.45%
3 months+15.25%
6 months+24.42%
Current year+7.90%
1 week 11.79
Extreme 11.79
14.42
1 month 11.63
Extreme 11.63
17.3
Current year 9.95
Extreme 9.95
17.5
1 year 9.95
Extreme 9.95
17.5
3 years 9.95
Extreme 9.95
17.5
5 years 9.95
Extreme 9.95
17.5
10 years 9.95
Extreme 9.95
17.5
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Tax

Chief Executive Officer

-71,920 0.0669%
20/07/26 Other

Chief Executive Officer

8,35,791 0.3889%
20/07/26 Conversion -30,000 1.3913%
Change 5-day change 1-year change 3-year change Capi.($)
+11.85%+19.66%+31.65% - 137.21Cr
+2.41%+0.29%+42.02%+71.57% 6.47TCr
-0.15%+7.50%+11.01%+73.48% 5.48TCr
+0.57%+4.60%+10.07%+92.86% 5.35TCr
+0.37%+4.67%+27.03%+52.07% 4.6TCr
-1.21%+2.32%+21.80%+123.81% 4.29TCr
-0.37%+5.07%+249.91%+918.74% 4.01TCr
+0.05%+0.21%+18.26%+58.53% 3.35TCr
-0.38%+5.68%+36.43%+27.54% 2.37TCr
+1.19%-4.98%+29.01%-0.65% 2.4TCr
Average +1.43%+3.71%+47.72%+157.55% 3.84TCr
Weighted average by Cap. +0.43%+2.78%+47.51%+158.58%

Financials

2026 *2027 *
Net sales 10Cr 9.15Cr 8.45Cr 7.66Cr 14Cr 972.2Cr 15Cr 101.67Cr 40Cr 509.37Cr 38Cr 38Cr 1.61TCr 11Cr 10Cr 9.39Cr 8.51Cr 16Cr 1.08TCr 16Cr 113.01Cr 45Cr 566.2Cr 43Cr 42Cr 1.79TCr
Net income -18Cr -16Cr -14Cr -13Cr -24Cr -1.66TCr -25Cr -173.84Cr -69Cr -870.98Cr -66Cr -64Cr -2.75TCr -25Cr -22Cr -20Cr -18Cr -34Cr -2.33TCr -35Cr -243.96Cr -97Cr -1.22TCr -92Cr -90Cr -3.85TCr
Net Debt - -
Projected Income Statement - Annual - Freenome, Inc.
Logo Freenome, Inc.
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
Employees
378
Date Price Change Volume
23/26/23 $12.77 -2.52% 6,12,770
22/26/22 $13.10 -6.50% 5,86,697
21/26/21 $14.01 -0.36% 3,81,705
20/26/20 $14.06 +11.85% 8,60,694
19/26/19 $12.57 +6.98% 6,49,374
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.77USD
Average target price
18.00USD
Spread / Average Target
+40.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Freenome, Inc.
  1. Stock Market
  2. Stocks
  3. FRNM Stock